2014 Annual Meeting | 2CO.001 - Research and Technology Colloquium: From Discovery to Therapy

Date Sunday 04/27/14

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Colloquium

Director(s) Wendy R. Galpern, MD, PhD, FAAN

Topic(s)

Learning Objectives Attendees should have an increased understanding of the steps involved in drug discovery and development as well as the challenges inherent to each stage. Additionally, attendees will learn about associated regulatory requirements.

CME Available No CME available

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Didactic, Interactive, Audience Participation

Event Timeline
08:00 AM - 08:10 AM		Introduction Wendy R. Galpern, MD, PhD, FAAN
08:10 AM - 08:40 AM		Discovery of Novel Therapeutic agents for CNS Disorders: Target Selection and Discovery Process Peter J. Conn, PhD
08:40 AM - 09:10 AM		Translating Scientific Discovery into a Novel Therapy in the Academic Setting Charles A. Thornton, MD, FAAN
09:10 AM - 09:40 AM		Early Stage Development: Decisions and Challenges Steven M. Paul, MD
09:40 AM - 09:55 AM		Break
09:55 AM - 10:25 AM		Late Stage Development: Decisions and Challenges Ira Shoulson, MD
10:25 AM - 10:55 AM		Development of Cell and Gene Therapies Wilson W. Bryan, MD
10:55 AM - 11:25 AM		Discussion
11:25 AM - 11:55 AM		Questions and Answers
11:55 AM - 12:00 PM		Wrap-Up and Summary Wendy R. Galpern, MD, PhD, FAAN

Faculty Disclosures
Wendy R. Galpern, MD, PhD, FAAN	No disclosure on file
Charles A. Thornton, MD, FAAN	Dr. Thornton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Thornton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Thornton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Thornton has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne. Dr. Thornton has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pepgen. The institution of Dr. Thornton has received research support from Marigold Foundation. The institution of Dr. Thornton has received research support from NIH. The institution of Dr. Thornton has received research support from Muscular Dystrophy Association . The institution of Dr. Thornton has received research support from Dyne. The institution of Dr. Thornton has received research support from Avidity. The institution of Dr. Thornton has received research support from Ionis. Dr. Thornton has received intellectual property interests from a discovery or technology relating to health care.
Ira Shoulson, MD	Dr. Shoulson has received research support from Vaccinex.
Wilson W. Bryan, MD	Dr. Bryan has received personal compensation in the range of $100,000-$499,999 for serving as a Director, Office of Tissues and Advanced Therapies with United States Food and Drug Administration (FDA).
Peter J. Conn, PhD	No disclosure on file
Steven M. Paul, MD	No disclosure on file